Replies to post #19047 on NorthWest Biotherapeutics Inc (NWBO)

[PacificNW]

Thanks.
I would like confirmation of the land if you don't mind. I have never heard of buying a facility where land is not included, afterall the building is part of the land and they don't look like condos imho. I would think that NWBO would be charging Cognate a healthy sum to use our state of the art facilities. So all Cognate has it its patented production capabilities? Who developed those capabilities btw and when?

[Evaluate]

Memphis facility ... see post 14617 and 14676

http://www.bizjournals.com/memphis/stories/2007/01/08/daily40.html

http://bioworksbusiness.com/newsDet.cfm?newsID=307

www.commercialappeal.com/news/2007/nov/08/tigenix-invests-in-memphis-facility/


http://www.cognatebioservices.com/facilities-2/

FACILITIES
Cognate is headquartered in Baltimore, MD USA, housing our research and development and process development laboratories.
Cognate’s state of the art cGMP facility is strategically located in Memphis, TN USA – a worldwide air hub for both FedEx and UPS, enabling Cognate to send and receive shipments from anywhere in the US within 24 hours, with multiple choices of carriers. This enables Cognate to handle both fresh and frozen cell products of all types.

also:

http://www.wikinvest.com/stock/Northwest_Biotherapeutcs_(NWBO)/Cognate

On May 17, 2007, the Company entered into a new services agreement with Cognate pursuant to which Cognate will provide certain consulting and, when needed, manufacturing services to the Company for its DCVax®-Brain Phase II clinical trial. Under the terms of the new contract, the Company paid a non-refundable contract initiation fee of $250,000 and committed to pay budgeted monthly service fees of $400,000, subject to quarterly true-ups, and monthly facility fees of $150,000.

and:
http://sec.edgar-online.com/northwest-biotherapeutics-inc/10-ka-amended-annual-report/2011/01/26/section27.aspx

Cognate has moved its operations from Sunnyvale Califormia to Memphis Tennessee where it has purchased an existing cGMP (clean room manufacturing under current Good Manufacturing Practices) facility that is fully functional. The capacity in Memphis is approximately 600 patients per year, which we believe will be sufficient for our Phase II clinical trial for DCVax ® -Brain. We have a plan with Cognate to accommodate an increase in production capacity based on demand and have detailed plans and cost analysis for additional modular expansions which should increase the capacity of the current facilities from approximately 600 patients to over 9,000 patients per year.